Allen Institute for Artificial Intelligence logo

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 7 months ago

Possible Interaction: Debrisoquin and Quinidine



Research Papers that Mention the Interaction

The extent to which quinidine altered these indices of encainide disposition was highly correlated with the metabolic ratio for debrisoquine oxidation (r = 0.62-0.95).
The Journal of pharmacology and experimental therapeutics  •  1989  |  View Paper
By pre-treatment with a typical CYP2D6 inhibitor, quinidine , the AUC0-8 value of 4-OH DB in High was decreased although such values in Low and uPA-/-/SCID mice did not change.
Journal of pharmaceutical sciences  •  2007  |  View Paper
Although both quinidine and quinine are competitive inhibitors of debrisoquine 4-hydroxylase activity in rat and man, their potency is reversed.
Quinidine is a potent inhibitor of debrisoquine 4-hydroxylase activity of human liver (IC50: 3.6 microM).
Biochemical pharmacology  •  1989  |  View Paper
However, two of them were on quinidine , a well known inhibitor of debrisoquine oxidation.
International Ophthalmology  •  2005  |  View Paper
In their study, they have also demonstrated that quinidine inhibits both CYP2D6- and CYP1A1-mediated debrisoquine 4-hydroxylation.
Drug metabolism and disposition: the biological fate of chemicals  •  2003  |  View Paper
Both the S(+)-4- and 7-hydroxylations of debrisoquine were inhibited by quinidine in both populations.
Pharmacogenetics  •  1993  |  View Paper
A single oral dose (50 mg) of quinidine significantly increased the debrisoquine metabolic ratio in six healthy volunteers.
It is concluded that quinidine , but not its diastereoisomer quinine, is a potent selective inhibitor of the in vivo oxidation of debrisoquine and can produce an artifactual PM phenocopy in persons who are phenotypically extensive metaboliser (EM) phenotype status.
Chirality  •  1991  |  View Paper
Biotransformation of substrates for the debrisoquine pathway can be markedly perturbed by even low doses of quinidine ; interindividual variability in drug interactions may have a genetic component.
British journal of clinical pharmacology  •  1989  |  View Paper
Quinidine was a potent inhibitor of the 4-hydroxylation of debrisoquine and the 1'-hydroxylation of bufuralol, with IC50 values of 0.7 and 0.2 microM, being around 100 times more potent in this respect than quinine.
British journal of clinical pharmacology  •  1986  |  View Paper